Feb 07, 2019 8:00am EST Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
Jan 07, 2019 7:30am EST Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
Oct 25, 2018 4:30pm EDT Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
Oct 20, 2018 10:45am EDT Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
Oct 08, 2018 6:10pm EDT Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
Sep 07, 2018 1:14pm EDT Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
Sep 05, 2018 7:30am EDT Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Aug 15, 2018 7:30am EDT Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
